Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2026)

Roivant Sciences' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• Quarterly Cash & Equivalents fell 47.73% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 47.73% YoY) and the FY2026 annual result came in at $1.4 billion, down 47.73% from the prior year.
• Cash & Equivalents was $1.4 billion for Q1 2026 at Roivant Sciences, down from $1.5 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $6.7 billion in Q4 2023 and bottomed at $99.1 million in Q4 2024.
• A 5-year average of $2.4 billion and a median of $1.6 billion in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 98.52% — and 2025, when it jumped 1391.95%.
• Roivant Sciences' Cash & Equivalents stood at $1.5 billion in 2022, then surged by 338.64% to $6.7 billion in 2023, then plunged by 98.52% to $99.1 million in 2024, then soared by 1391.95% to $1.5 billion in 2025, then decreased by 3.99% to $1.4 billion in 2026.
• Business Quant data shows ROIV's Cash & Equivalents at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.2 billion in Q3 2025.